Skip to content
DataLookout
Menu

NCT07402876

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 years 11 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Dec 2026 to Dec 2029
    • Start date: Feb 2026 to Dec 2027
    • Eligibility criteria expanded, about 9 words
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of clearance of lymphomatous vitreous cells compared across ICM and monthly ADX-2191 treatment groups after eight weeks of treatment
Timeframe: Eight weeks

Arms and interventions

Induction/Consolidation/Maintenance (ICM) ADX-2191 injectionExperimental
Monthly ADX-2191 injectionActive comparator

Drugs: ICM ADX-2191 injection, Monthly ADX-2191 injection

Sites

1 site in 1 country

  • Bascom Palmer Eye InstituteMiami, Florida, United States